Since the activation of ATM-CHK2 and ATR-CHK1 supports DNA repair and survival processes in CPT-11-treated colon cancer cells [7, 16–19], a combination of CPT-11 with inhibitors of these kinases could be a therapeutic option. Here, CHEK1 is linked to malignant colon neoplasm.